M. D. Caballero Barrigón

Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma.

G. Salles, S. Montoto, H. Holte, 2021, European journal of cancer.

Detection of single and associated lesions of the Bcl-1, Bcl-2, Bcl-6, c-myc, p53 and p16 genes in B-cell non-Hodgkin's lymphomas: value of molecular analysis for a better assignment of the histologic subtype.

J. S. San Miguel, M. D. del Carmen, R. García-Sanz, 1998, Haematologica.

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.

A. López-Guillermo, F. Bosch, A. Nagler, 2019, The Lancet. Haematology.

Graft versus host disease-related eosinophilic fasciitis: cohort description and literature review

L. Lopez-Corral, M. D. Caballero Barrigón, C. Hidalgo Calleja, 2022, Advances in Rheumatology.

Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis.

E. Kimby, G. Salles, A. López-Guillermo, 2018, The Lancet. Haematology.

Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial

G. Salles, M. Shipp, P. Zinzani, 2017 .

[New modalities in hematopoietic stem cell transplant].

M. D. Caballero Barrigón, M. D. C. Barrigón, 2009, Medicina clinica.